COLORADO SPRINGS, Colo., Dec. 14, 2010 /PRNewswire/ — Cannabis
Science, Inc. (OTC Bulletin Board:
CBIS) a pioneering U.S. biotech company developing
pharmaceutical cannabis products, is pleased to announce it has
signed a lease for a new corporate headquarters as its new base of
operations in Denver, Colorado. The 6,600 sq. ft. core facility at
2422 S. Trenton Way, Unit H will be dedicated to housing executive
offices, administrative personnel, as well as the Lab Division core
of operations for its cannabis formulations testing and FDA
initiatives.
“Needless to say we are very happy that with the support and
patience of our investors we have achieved this milestone. This
facility will be the Cannabis Science core and is an instrumental
step in accomplishing our short and long-term goals of carrying out
the basic and applied research needed to provide the best Cannabis
Science products to patients. Uniquely, Cannabis Science will serve
both the dispensary market, through licensing our technologies and
analytical capabilities, and the pharmaceutical market, by working
through the FDA approval process,” stated Dr. Robert Melamede,
CEO.
The company has executed a five-year lease on the facility in
order to provide stable growth during our development phase. In our
new corporate headquarters, the Company will facilitate customer
communications while we mature our operations. Up till now, the
Company has focused on developing out corporate structure and
preliminary financial base. We now have the facility to centralize
and expand our staff. As we expand our infrastructure, we will be
more responsive to the overwhelming number of inquiries that we
receive from patients, investors and the media.
The new laboratory facility will include analytical chemistry
and genetic instrumentation, extraction equipment, as well as
genetic and cell culture facilities. Our intent is t
‘/>”/>
SOURCE